JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265807

Human SLCO4A1 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

SLCO4A1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human SLCO4A1 knockout HeLa cell line (AB265807)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLCO4A1 knockout HeLa cell line (AB265807)

Allele-3 : Insertion of the selection cassette in exon 2.

Sanger Sequencing - Human SLCO4A1 knockout HeLa cell line (AB265807)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLCO4A1 knockout HeLa cell line (AB265807)

Allele-2 : 1 bp insertion in exon 2.

Sanger Sequencing - Human SLCO4A1 knockout HeLa cell line (AB265807)
  • Sanger seq

Unknown

Sanger Sequencing - Human SLCO4A1 knockout HeLa cell line (AB265807)

Allele-1 : 1 bp deletion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265807-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265807 Human SLCO4A1 knockout HeLa cell line", "number":"AB265807-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265807-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265807-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265807 Human SLCO4A1 knockout HeLa cell line", "number":"AB265807-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265807-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265807-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265807 Human SLCO4A1 knockout HeLa cell line", "number":"AB265807-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265807-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265807 Human SLCO4A1 knockout HeLa cell line", "number":"AB265807-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
SLCO4A1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

SLCO4A1 also known as solute carrier organic anion transporter family member 4A1 functions as a transporter protein involved in the translocation of organic anions across cell membranes. With an approximate mass of 80 kDa SLCO4A1 facilitates the movement of large often negatively charged molecules playing a part in cellular uptake processes. Its expression is noticeable in several tissues including the liver kidney and heart indicating its role in the systemic circulation and excretion of various substrates.
Biological function summary

SLCO4A1 is engaged in the transport of hormones drugs and metabolites across cellular compartments. It belongs to the larger family of solute carriers and does not necessarily form part of a multi-protein complex operating as a standalone transporter. Its activity influences the cellular internalization of various biologically active compounds marking its importance in balancing intracellular and extracellular concentrations.

Pathways

SLCO4A1 integration is seen in critical pathways like drug metabolism and steroid hormone metabolism. In the context of drug metabolism it works alongside cytochrome P450 enzymes to ensure the proper processing and elimination of pharmaceutical compounds. In steroid hormone metabolism it interacts with proteins such as SHBG (sex hormone-binding globulin) to modulate hormone bioavailability influencing physiological responses.

SLCO4A1 shows connections to conditions such as cholestasis and certain drug-induced toxicities. In cholestasis the impaired function of SLCO4A1 can disrupt bile acid transport aggravating liver function issues. Furthermore its interplay with hepatic transporters like SLCO1B1 can affect drug pharmacokinetics raising susceptibility to drug-induced liver injury. Understanding these interactions aids in assessing risk factors associated with SLCO4A1 dysfunction in disease states.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com